RU2649004C2 - Антагонисты cxcr7 - Google Patents

Антагонисты cxcr7 Download PDF

Info

Publication number
RU2649004C2
RU2649004C2 RU2015125544A RU2015125544A RU2649004C2 RU 2649004 C2 RU2649004 C2 RU 2649004C2 RU 2015125544 A RU2015125544 A RU 2015125544A RU 2015125544 A RU2015125544 A RU 2015125544A RU 2649004 C2 RU2649004 C2 RU 2649004C2
Authority
RU
Russia
Prior art keywords
mmol
mixture
pyrazin
cancer
added
Prior art date
Application number
RU2015125544A
Other languages
English (en)
Russian (ru)
Other versions
RU2015125544A (ru
Inventor
Джунфа ФАН
Энтони КРАСИНСКИ
Кристофер В. ЛЭНГ
Ребекка М. ЛЮ
Джеффри П. МакМАХОН
Джей П. Пауэрс
Ибинь Цзэн
Пэнли ЧЖАН
Original Assignee
Кемосентрикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кемосентрикс, Инк. filed Critical Кемосентрикс, Инк.
Publication of RU2015125544A publication Critical patent/RU2015125544A/ru
Application granted granted Critical
Publication of RU2649004C2 publication Critical patent/RU2649004C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2015125544A 2012-11-29 2013-11-26 Антагонисты cxcr7 RU2649004C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731463P 2012-11-29 2012-11-29
US61/731,463 2012-11-29
PCT/US2013/072067 WO2014085490A1 (en) 2012-11-29 2013-11-26 Cxcr7 antagonists

Publications (2)

Publication Number Publication Date
RU2015125544A RU2015125544A (ru) 2017-01-10
RU2649004C2 true RU2649004C2 (ru) 2018-03-29

Family

ID=50825654

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015125544A RU2649004C2 (ru) 2012-11-29 2013-11-26 Антагонисты cxcr7

Country Status (16)

Country Link
US (5) US9169261B2 (https=)
EP (1) EP2925745B1 (https=)
JP (1) JP6272897B2 (https=)
KR (1) KR102196374B1 (https=)
CN (1) CN105189484B (https=)
AU (1) AU2013352304C1 (https=)
BR (1) BR112015012366A8 (https=)
CA (1) CA2892042C (https=)
DK (1) DK2925745T3 (https=)
ES (1) ES2681593T3 (https=)
IL (1) IL238974B (https=)
MX (1) MX359651B (https=)
PT (1) PT2925745T (https=)
RU (1) RU2649004C2 (https=)
SG (1) SG11201504212WA (https=)
WO (1) WO2014085490A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359651B (es) 2012-11-29 2018-10-05 Chemocentryx Inc Antagonistas de cxcr7.
WO2016040508A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
BR112017018119B1 (pt) 2015-02-24 2021-11-03 Bayer Cropscience Aktiengesellschaft Processo para a preparação de triazóis
EP4302834A3 (en) 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
MA45782B1 (fr) * 2016-07-28 2021-12-31 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur de cxcr7 pipéridine
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
JP7240319B2 (ja) * 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
EP3713934B1 (en) 2017-11-23 2022-04-13 Universita' degli Studi di Palermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての多環式化合物
WO2019145460A1 (en) * 2018-01-26 2019-08-01 Idorsia Pharmaceuticals Ltd Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
CN108794484B (zh) * 2018-04-28 2020-04-24 北京施安泰医药技术开发有限公司 [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用
MX2021006915A (es) 2018-12-12 2021-08-24 Chemocentryx Inc Inhibidores de cxcr7 para el tratamiento de cancer.
CN110013483B (zh) * 2019-05-10 2022-04-15 江苏师范大学 噻唑并[3,2-a]嘧啶-6-甲腈衍生物用于抗菌的用途
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
TWI879949B (zh) 2020-04-27 2025-04-11 南韓商奧土擇破利悟股份有限公司 用於ｕｂｒ盒結構域配體之化合物、組成物以及醫藥組成物
CN113105469B (zh) * 2021-04-13 2022-04-22 中国科学院新疆理化技术研究所 一种三环呋喃并[2,3-d]嘧啶酮类化合物及用途
EP4326257A4 (en) * 2021-04-19 2025-03-12 ChemoCentryx, Inc. AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS
WO2024042480A1 (en) 2022-08-26 2024-02-29 Suven Life Sciences Limited Heteroaromatic compounds for the treatment of neurological disorders
PY24116080A (es) 2024-01-03 2025-08-04 Pi Industries Ltd Amidas heterociclicas biciclicas para combatir hongos fitopatógenos

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2178414C2 (ru) * 1996-03-29 2002-01-20 Дюфар Интернэшнл Рисерч Б.В. Производные пиперазина и пиперидина и способ их получения
RU2241712C9 (ru) * 1998-12-31 2006-04-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентификс Сас Производные имидазола как ингибиторы пренилтрансферазы, фармацевтическая композиция и способы лечения на их основе
US20070167443A1 (en) * 2005-11-10 2007-07-19 Chemocentryx, Inc. Substituted quinolones and methods of use
US20070275965A1 (en) * 2006-03-30 2007-11-29 Chemocentryx, Inc. CXCR4 modulators
US20100150831A1 (en) * 2008-11-04 2010-06-17 Chemocentryx, Inc. Modulators of cxcr7
WO2012022265A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4966691A (https=) 1972-10-30 1974-06-27
DE60007745T2 (de) * 1999-06-30 2005-03-10 Bristol-Myers Squibb Co. Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
EP1301484A2 (en) 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin receptor ligands
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
CA2448080A1 (en) 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
MXPA04008797A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Inhibidores de histona desacetilasa.
WO2004009587A1 (en) 2002-07-22 2004-01-29 Orchid Chemicals & Pharmaceuticals Ltd Oxazolidinone derivatives as antibacterial agents
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
WO2005074645A2 (en) 2004-02-03 2005-08-18 Chemocentryx, Inc. Methods and compositions for modulating angiogenesis
AU2006230674A1 (en) 2004-03-18 2006-11-16 The Brigham And Women's Hospital, Inc. Methods for the Treatment of Synucleinopathies
EP1637529A1 (en) 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
WO2006038989A1 (en) * 2004-09-29 2006-04-13 Chemocentryx, Inc. Substituted arylamides
WO2006100461A1 (en) 2005-03-23 2006-09-28 Astrazeneca Ab 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
AU2006263657A1 (en) * 2005-06-29 2007-01-04 Chemocentryx, Inc. Substituted N-cinnamyl benzamides
WO2007111275A1 (ja) 2006-03-24 2007-10-04 The University Of Tokyo シグナル伝達阻害方法、それに用いるシグナル伝達阻害剤およびその用途
EP2001485B1 (en) 2006-03-29 2015-09-09 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists
WO2007115232A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
US20090192143A1 (en) 2006-07-14 2009-07-30 Cox Christopher D Substituted diazepan orexin receptor antagonists
BRPI0714440A2 (pt) 2006-07-21 2013-04-24 Irm Llc composto inibidor de itpkb, uso do mesmo e composiÇço farmacÊutica
WO2008020229A2 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
US20080293711A1 (en) 2007-03-08 2008-11-27 Clark Michael P Chemokine receptor modulators
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US8853202B2 (en) 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
US20110014121A1 (en) 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
GB0822981D0 (en) * 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CN102372717B (zh) * 2010-08-20 2014-06-18 和记黄埔医药（上海）有限公司 吡咯并嘧啶类化合物及其用途
EP2616442B8 (en) 2010-09-14 2018-10-17 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
MX359651B (es) 2012-11-29 2018-10-05 Chemocentryx Inc Antagonistas de cxcr7.
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
MX2021006915A (es) 2018-12-12 2021-08-24 Chemocentryx Inc Inhibidores de cxcr7 para el tratamiento de cancer.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2178414C2 (ru) * 1996-03-29 2002-01-20 Дюфар Интернэшнл Рисерч Б.В. Производные пиперазина и пиперидина и способ их получения
RU2241712C9 (ru) * 1998-12-31 2006-04-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентификс Сас Производные имидазола как ингибиторы пренилтрансферазы, фармацевтическая композиция и способы лечения на их основе
US20070167443A1 (en) * 2005-11-10 2007-07-19 Chemocentryx, Inc. Substituted quinolones and methods of use
US20070275965A1 (en) * 2006-03-30 2007-11-29 Chemocentryx, Inc. CXCR4 modulators
US20100150831A1 (en) * 2008-11-04 2010-06-17 Chemocentryx, Inc. Modulators of cxcr7
WO2012022265A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof

Also Published As

Publication number Publication date
CN105189484A (zh) 2015-12-23
KR20160002667A (ko) 2016-01-08
EP2925745A1 (en) 2015-10-07
MX2015006412A (es) 2015-10-29
US11834452B2 (en) 2023-12-05
CA2892042C (en) 2022-06-14
EP2925745A4 (en) 2016-06-15
BR112015012366A2 (pt) 2017-07-11
IL238974B (en) 2019-03-31
US20200095251A1 (en) 2020-03-26
EP2925745B1 (en) 2018-04-04
SG11201504212WA (en) 2015-06-29
RU2015125544A (ru) 2017-01-10
AU2013352304B2 (en) 2017-08-31
US9169261B2 (en) 2015-10-27
US11059825B2 (en) 2021-07-13
IL238974A0 (en) 2015-07-30
DK2925745T3 (en) 2018-07-23
US10287292B2 (en) 2019-05-14
MX359651B (es) 2018-10-05
JP2016502538A (ja) 2016-01-28
AU2013352304C1 (en) 2018-03-22
US9783544B2 (en) 2017-10-10
US20180086766A1 (en) 2018-03-29
KR102196374B1 (ko) 2020-12-31
CA2892042A1 (en) 2014-06-05
CN105189484B (zh) 2018-05-04
US20160145259A1 (en) 2016-05-26
US20220127272A1 (en) 2022-04-28
WO2014085490A1 (en) 2014-06-05
HK1214264A1 (en) 2016-07-22
JP6272897B2 (ja) 2018-01-31
BR112015012366A8 (pt) 2019-10-01
US20140154179A1 (en) 2014-06-05
ES2681593T3 (es) 2018-09-14
AU2013352304A1 (en) 2015-06-04
PT2925745T (pt) 2018-08-08

Similar Documents

Publication Publication Date Title
RU2649004C2 (ru) Антагонисты cxcr7
CN102271681B (zh) Cxcr7调节剂
ES2648340T3 (es) Benzoimidazoles y benzopirazoles substituidos como antagonistas de CCR(4)
CN115335043A (zh) Pgdh抑制剂以及制备和使用方法
RS62809B1 (sr) Modulatori ccr2
JP2013526524A (ja) Ｐｄｅ１０阻害剤としてのアリールおよびヘテロアリール窒素ヘテロ環式化合物
RU2666730C2 (ru) Диазольные лактамы
TW200811173A (en) Pyrazoloquinolones are potent PART inhibitors
BR112020006169A2 (pt) inibidores de quinase p38 que reduzem dux4 e expressão de gene a jusante para o tratamento de fshd
EA015710B1 (ru) Триазолил фенилбензолсульфонамиды
US20100311712A1 (en) Modulators of cxcr7
HK1214264B (en) Cxcr7 antagonists
US20110014121A1 (en) Modulators of cxcr7
TW202309016A (zh) 作為cxcr7抑制劑之吖丁啶基-乙醯胺